Thermo Fisher Scientific (NYSE:TMO) Shares Acquired Sen. Markwayne Mullin

Senator Markwayne Mullin (R-Oklahoma) recently bought shares of Thermo Fisher Scientific Inc. NYSE: TMO. In a filing disclosed on June 11th, the Senator disclosed that they had bought between $15,001 and $50,000 in Thermo Fisher Scientific stock on May 13th.

Senator Markwayne Mullin also recently made the following trade(s):

• Purchased $50,001 - $100,000 in shares of Valero Energy NYSE: VLO on 5/13/2025.
• Purchased $15,001 - $50,000 in shares of LPL Financial NASDAQ: LPLA on 5/13/2025.
• Purchased $50,001 - $100,000 in shares of Chevron NYSE: CVX on 5/13/2025.
• Purchased $50,001 - $100,000 in shares of Zoetis NYSE: ZTS on 5/13/2025.
• Purchased $15,001 - $50,000 in shares of L3Harris Technologies NYSE: LHX on 5/13/2025.
• Purchased $15,001 - $50,000 in shares of Adobe NASDAQ: ADBE on 5/13/2025.
• Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 5/13/2025.
• Purchased $15,001 - $50,000 in shares of Texas Instruments NASDAQ: TXN on 5/13/2025.
• Purchased $15,001 - $50,000 in shares of ConocoPhillips NYSE: COP on 5/13/2025.
• Purchased $15,001 - $50,000 in shares of Applied Materials NASDAQ: AMAT on 5/13/2025.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded up $3.58 during mid-day trading on Friday, hitting $478.61. The stock had a trading volume of 4,191,526 shares, compared to its average volume of 3,108,119. The company's 50 day simple moving average is $413.76 and its 200 day simple moving average is $469.70. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.38 and a current ratio of 1.93. The stock has a market cap of $180.67 billion, a price-to-earnings ratio of 27.68, a PEG ratio of 2.48 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the business posted $5.37 earnings per share. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.36%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Raymond James Financial restated an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Evercore ISI lowered their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Robert W. Baird raised their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, Royal Bank Of Canada lowered their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president owned 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds have recently added to or reduced their stakes in TMO. Semus Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 4.0% during the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock valued at $245,000 after purchasing an additional 18 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Proactive Wealth Strategies LLC boosted its stake in Thermo Fisher Scientific by 2.7% during the fourth quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock worth $392,000 after acquiring an additional 20 shares in the last quarter. Cassaday & Co Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 0.9% in the fourth quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock worth $1,189,000 after purchasing an additional 20 shares during the period. Finally, Callan Capital LLC grew its holdings in Thermo Fisher Scientific by 2.7% in the fourth quarter. Callan Capital LLC now owns 773 shares of the medical research company's stock worth $402,000 after purchasing an additional 20 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father's plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.